|
Unilateral cleft palate
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Also, binding of Zn(II) and Cu(II) by GMP-1 is weaker than the 8-hydroxyquinoline scaffold compound clioquinol previously tested in AD clinical trials.
|
31839606 |
2020 |
|
Alzheimer's Disease
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The opposite effect of Aβ and oxidative/excitotoxic stimuli on SUMO1 modification may cause the pathological stage-associated change in the level of SUMO-modified proteins in the AD mouse brain.
|
29660340 |
2018 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
SUMO1 impact on Alzheimer disease pathology in an amyloid-depositing mouse model.
|
29217476 |
2018 |
|
Alzheimer's Disease
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Interestingly, we did not observe any alteration in the levels of SUMO1-conjugation related to Alzheimer's disease.
|
29633471 |
2018 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Development of GMP-1 a molecular chaperone network modulator protecting mitochondrial function and its assessment in fly and mice models of Alzheimer's disease.
|
29704317 |
2018 |
|
Alzheimer's Disease
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We found that rs12472035 polymorphism of SUMO1 was significantly associated with an increased risk of AD in male group (the CT genotype of rs12472035: adjusted OR=8.737, 95% CI=2.041-37.41, p-value=0.003).
|
27084229 |
2016 |
|
Alzheimer's Disease
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
We show that tau SUMOylation induces tau hyperphosphorylation at multiple AD-associated sites, whereas site-specific mutagenesis of tau at K340R (the SUMOylation site) or simultaneous inhibition of tau SUMOylation by ginkgolic acid abolishes the effect of small ubiquitin-like modifier protein 1 (SUMO-1).
|
25378699 |
2014 |
|
Alzheimer's Disease
|
0.090 |
Biomarker
|
disease |
BEFREE |
Our study indicates SUMO1 is not only a novel and potent regulator of BACE1 accumulation and Aβ generation but also a potential therapeutic target for Alzheimer's disease.
|
22975420 |
2013 |
|
Alzheimer's Disease
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Further, overexpression of the SUMO E2 enzyme ubc9 along with SUMO-1 results in decreased levels of Abeta aggregates in cells transfected with the familial Alzheimer's disease-associated V642F mutant APP, indicating the potential of up-regulating activity of the cellular sumoylation machinery as an approach against Alzheimer's disease.
|
18675254 |
2008 |
|
Acute Promyelocytic Leukemia
|
0.080 |
AlteredExpression
|
disease |
BEFREE |
Arsenic trioxide (ATO) known to act as an antileukemic agent for acute promyelocytic leukemia (APL) not only enhanced EVI1 sumoylation but also enhanced the co-localization of EVI1 and SUMO1 in nuclear bodies distinct from PML nuclear bodies.
|
23770046 |
2013 |
|
Acute Promyelocytic Leukemia
|
0.080 |
Biomarker
|
disease |
BEFREE |
In the nucleus, ErbB4 colocalized with PIAS3 and SUMO-1 in promyelocytic leukemia nuclear bodies, nuclear domains involved in regulation of transcription.
|
22584572 |
2012 |
|
Acute Promyelocytic Leukemia
|
0.080 |
Biomarker
|
disease |
BEFREE |
Adenovirus E1B 55-kilodalton protein is a p53-SUMO1 E3 ligase that represses p53 and stimulates its nuclear export through interactions with promyelocytic leukemia nuclear bodies.
|
20861261 |
2010 |
|
Acute Promyelocytic Leukemia
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, using an astroglial cell line, primary culture of astrocytes, and tissue samples from G93A-SOD1 mice, we show that CTE-SUMO-1 is targeted to promyelocytic leukemia nuclear bodies.
|
17823119 |
2007 |
|
Acute Promyelocytic Leukemia
|
0.080 |
Biomarker
|
disease |
BEFREE |
We found that SP100, SUMO-1 and other proteins from the promyelocytic leukemia nuclear bodies (NBs) form a large body that co-localizes with the HP1 signal.
|
15470359 |
2005 |
|
Acute Promyelocytic Leukemia
|
0.080 |
Biomarker
|
disease |
BEFREE |
PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia.
|
10373566 |
1999 |
|
Acute Promyelocytic Leukemia
|
0.080 |
Biomarker
|
disease |
BEFREE |
In APL cases with cryptic PML-RARalpha rearrangements, the characteristic microparticulate pattern of PML staining was detected with partial colocalization with PIC 1, indicative of disruption of the nuclear bodies; whereas in t(11; 17)-associated APL, PML and PIC 1 remained colocalized within discrete nuclear bodies, as observed in non-APL cases.
|
9389704 |
1997 |
|
Acute Promyelocytic Leukemia
|
0.080 |
Biomarker
|
disease |
BEFREE |
PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia.
|
8806687 |
1996 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Our results indicated that the SUMO1 acceptor site of NRF2 is the conserved lysine residue 110 (K110), and that NRF2 SUMOylation deficiency inhibited tumorigenesis in hepatocellular carcinoma (HCC).
|
31546024 |
2019 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Our findings identify SUMO1 as a novel key regulator of EphB1-mediated tumorigenesis.
|
29550816 |
2018 |
|
Carcinogenesis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
An increased immunohistochemical expression of Snail1, Sumo1, TβRI, Hes1, and c-Jun was observed in aggressive prostate cancer tissues, consistent with their functional roles in tumorigenesis.
|
29228645 |
2017 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
Apart from their structural similarities the four proteins progesterone membrane component 1 (PGRMC1, also referred to as IZA, sigma-2 receptor, Dap1), PGRMC2, neudesin (NENF) and neuferricin (CYB5D2) display surprisingly divergent and multifunctional physiological properties related to cholesterol/steroid biosynthesis, drug metabolism and response, iron homeostasis, heme trafficking, energy metabolism, autophagy, apoptosis, cell cycle regulation, cell migration, neural functions, and tumorigenesis and cancer progression.
|
28396637 |
2017 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
The soft-agar colony formation, migration, vasculogenic mimicry (VM) and three-dimensional (3D) cell culture assays were performed to detect the phenotypes of tumor cells in vitro, and the xenograft tumor model in mice was conducted to verify that SUMO1 modification of KHSRP regulated tumorigenesis in vivo.
|
29020972 |
2017 |
|
Carcinogenesis
|
0.070 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of SUMO-1 in OLP was similar to NM and IFH, suggesting that alterations of this protein occur at later stages of carcinogenesis, because important overexpression occurred in oral epithelial dysplasia and OSCC.
|
23350884 |
2013 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
SUMO1 modification of PTEN regulates tumorigenesis by controlling its association with the plasma membrane.
|
22713753 |
2012 |